Effect of an oxygenating agent on oral bacteria in vitro and on dental plaque composition in healthy young adults

Fernandez y Mostajo, M.; van der Reijden, W.A.; Buijs, M.J.; Beertsen, W.; van der Weijden, F.; Crielaard, W.; Zaura, E.

DOI
10.3389/fcimb.2014.00095

Publication date
2014

Document Version
Final published version

Published in
Frontiers in Cellular and Infection Microbiology

License
CC BY

Citation for published version (APA):
Fernandez y Mostajo, M., van der Reijden, W. A., Buijs, M. J., Beertsen, W., van der Weijden, F., Crielaard, W., & Zaura, E. (2014). Effect of an oxygenating agent on oral bacteria in vitro and on dental plaque composition in healthy young adults. Frontiers in Cellular and Infection Microbiology, 4, [95]. https://doi.org/10.3389/fcimb.2014.00095

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
Effect of an oxygenating agent on oral bacteria in vitro and on dental plaque composition in healthy young adults

Mercedes Fernandez y Mostajo1*, Wil A. van der Reijden2, Mark J. Buijs1, Wouter Beertsen3, Fridus van der Weijden2, Wim Crielaard1 and Egija Zaura1

INTRODUCTION

Dental plaque biofilm is part of the oral microbiome that co-evolves in symbiosis with the human host (Marsh, 2012). Recently, the importance and beneficial role of the oral microbiome in maintaining oral and general health has been brought forward (Marsh, 2012; Hezel and Weitzberg, 2013). On the other hand, undisturbed dental plaque accumulation is associated with an enhanced host inflammatory response and gingival inflammation (gingivitis) (Lee et al., 2012). Gingivitis is known to be associated with the onset of periodontitis (Schatzle et al., 2003), therefore the importance of maintaining gingival health is well understood.

Although regular mechanical plaque removal is recommended for prevention of periodontal diseases, the quality of self-performed mechanical plaque removal may not always be sufficient (Hioe and van der Weijden, 2005). When this fails or cannot be optimally maintained, for instance in physically or mentally disabled populations, a chemical approach, such as the use of an antimicrobial mouthwash, can be an alternative or an adjunct.

Anti-plaque agents should not eradicate the oral microbiota. Instead, they should maintain the microbiota of the mouth at the level and composition that is compatible with oral health, this way preserving the beneficial functions of resident microbes (Marsh, 2012; ten Cate and Zaura, 2012). This requirement is not met by so-called broad spectrum antimicrobial agents such as chlorhexidine (CHX). Interestingly, oxygenating mouthwashes containing peroxoborate are able to reduce the dental plaque amount and retard the colonization and growth of anaerobes (Wennstrom and Lindhe, 1979; Binney et al., 1992; Moran et al., 1995) and Gram-negative bacteria (Hernandez et al., 2013). Gram-negative bacteria live in symbiosis with the host. Therefore, when mouthwashes are indicated, selective inhibition of taxa contributing to disease is preferred instead of broad-spectrum antimicrobials. The potential selectivity of an oxygenating mouthwash, Ardox-X® (AX), has not been assessed. The aim of this study was to determine the antimicrobial potential of AX and the effects of a twice-daily oral rinse on dental plaque composition.

Material and methods: In vitro, 16 oral bacterial strains were tested using agar diffusion susceptibility, minimum inhibitory and minimum bactericidal concentration tests. A pilot clinical study was performed with 25 healthy volunteers. Clinical assessments and microbiological sampling of supragingival plaque were performed at 1 month before the experiment (Pre-exp), at the start of the experiment (Baseline) and after the one-week experimental period (Post-exp). During the experiment individuals used AX mouthwash twice daily in absence of other oral hygiene measures. The microbiological composition of plaque was assessed by 16S rRNA gene amplicon sequencing.

Results: AX showed high inter-species variation in microbial growth inhibition. The tested Prevotella strains and Fusobacterium nucleatum showed the highest sensitivity, while streptococci and Lactobacillus acidophilus were most resistant to AX. Plaque scores at Pre-exp and Baseline visits did not differ significantly (p = 0.193), nor did the microbial composition of plaque. During a period of 7-days non-brushing but twice daily rinsing plaque scores increased from 2.21 (0.31) at Baseline to 2.43 (0.39) Post-exp. A significant microbial shift in composition was observed: genus Streptococcus and Veillonella increased while Corynebacterium, Haemophilus, Leptotrichia, Cardiobacterium and Capnocytophaga decreased (p ≤ 0.001).

Conclusion: AX has the potential for selective inhibition of oral bacteria. The shift in oral microbiome after 1 week of rinsing deserves further research.

Keywords: microbiome, selective inhibition, oxygenating agents, antimicrobials, Ardox-X®-technology
an aerobes are generally associated with oral infections (e.g., periodontitis, peri-implantitis, endodontic infections).

Among oxygenating agents, boron-derived compounds such as sodium perborate (peroxoborate) generate active oxygen in aqueous solutions. This characteristic is the basis for their use as bleaching agents in detergents, cleaning products and cosmetic preparations, as well as a preservative in eye drops (Safety, 2010). In clinical dentistry, boron-derived compounds are used as a bleaching agent for teeth and as an adjunct to CHX to counteract extrinsic staining of the tongue and tooth surfaces (Dona et al., 1998; Grundemann et al., 2000; van Maanen-Schakel et al., 2012; Feiz et al., 2014).

Ardox-X® technology (AX) was introduced to the market and promoted as a teeth whitening, anti-microbial, anti-fungal and anti-inflammatory compound (NGen Oral Pharma, www.ngenpharma.com). According to the manufacturer, the AX compound is formed by chemical complexation of peroxoborate with specific carriers such as glycerol and cellulose. This produces sodiumperborate-1,2-diol-glycerol/cellulose-ester adducts, i.e., single-reaction products containing all the atoms of all components. The manufacturer considers this to be a distinct molecular compound that provides controlled release of active oxygen without generating hydroxyl radicals. However, the scientific evidence for the antimicrobial efficacy of this compound is scarce. So far, only one in vitro study has been published which showed that AX has an antimicrobial effect against polymicrobial biofilm (microcosm) grown on titanium surfaces (Ntouka et al., 2011).

The aims of the current study were: first, to determine the antimicrobial effect of AX against oral bacteria in vitro; second, to evaluate in vivo the effect of AX containing mouthwash on the composition of undisturbed plaque accumulation in a one-week non-brushing model in healthy adults.

MATERIALS AND METHODS

IN VITRO STUDY

Bacterial strains (Table 1) were cultured on blood agar plates (Oxoid no 2, Oxoid, Basingstoke, UK) supplemented with 5% horse blood, 0.1% (w/v) haemin and 0.01% (w/v) menadione. For Tannerella forsythia Trypticase Soy Agar (TSA) (BBL, Beckton Dickson Microbiology Systems, Cockeysville, MD) was used supplemented with 5% horse blood, 0.1% (w/v) N-acetyl muraminic acid (TSNAM plates), 0.05% (w/v) haemin, and 0.01% (w/v) menadione (van der Reijden et al., 2006). All strains except Staphylococcus aureus were grown in anaerobic atmosphere containing 80% N₂, 10% CO₂, and 10% H₂. S. aureus was grown aerobically.

For this study, the manufacturer provided different concentrations of AX in standard equivalent units (SE) in a range 1–20 SE, where 1 SE contains 0.27% (w/v) of sodium perborate (SP), as well as the AX blank (AX without sodium perborate; NGen Oral Pharma); Curacao; van den Bosch, 2000, US patent number 6,017,515) that was used as negative control. As positive controls, two different concentrations of over-the-counter chlorhexidine (CHX) products were used: Perio Aid (0.12% CHX) (Dentaaid, Barcelona, Spain) and Corsodyl (0.2% CHX) (GlaxoSmithKline, Zeist, the Netherlands).

Agar diffusion tests were performed as described before (Clinical and Laboratory Standards Institute, 2009). For each strain, two blood agar plates were inoculated with 100 µl suspension of a single colony suspended in 5 ml phosphate buffered saline (PBS). The compounds were added in 5 mm holes punched in the agar. Five concentrations of AX (1.36; 1.9; 2.72; 4.08; 5.44%) together with a blank and two CHX concentrations were used. The blank and AX (2.72%) were included in each agar plate (twice per strain). Agar plates were incubated for 7 days at 37°C under anaerobic conditions (10% CO₂, 10% H₂, and 80% N₂). After incubation, plates were examined for growth inhibition. The inhibition zone around the holes was measured and expressed in mm from the edge to the nearest CFU.

Serial dilutions were used to determine the minimum inhibitory concentration (MIC) (Hecht, 2007) and the minimum bactericidal concentration (MBC) of AX. Two 24-wells plates were used per dilution set of 4 strains. The medium consisted of Brain Heart Infusion (BHI) broth (Oxoid, Basingstoke, UK) supplemented with 0.1% haemin and 0.01% menadione (h/m). For Tannerella forsythia filter-sterilized N-acetyl-muraminic acid (NAM) to a final concentration of 0.1% (w/v) was added. The compound was filter-sterilized (0.2 µm pore size; 7 bar max Whatman, Germany). The initial dilution for the MIC was prepared using 0.5 ml AX at the highest concentration (54.4 g/l) in two-fold serial dilution series (range 40–40, 800 mg/l).

Inocula were prepared from a pure culture of each strain. A single colony was taken using a sterile cotton pick and suspended in 5 ml of PBS. Then 50 µl of suspension were dispensed into each labeled well. Plates were incubated for 7 days at 37°C under anaerobic conditions (10% CO₂, 10% H₂, and 80% N₂). After 1 week the MICs were determined by visual means. The procedure was performed in triplicate at different time points.

After MIC determination, 100-µl samples from the various dilutions were inoculated onto appropriate agar plates and

| Strain Abbreviation |
|---------------------|
| Actinomyces naeslundii ATCC 12104 | An |
| Aggregatibacter actinomycetemcomitans HG 683* | Aa |
| Campylobacter rectus HG 963* | Cr |
| Fusobacterium nucleatum ATCC 25586 | Fn |
| Lactobacillus acidophilus ATCC 4356 | La |
| Parvimonas microa HG 1179* | Pm |
| Porphyromonas gingivalis K- HG 91* | Pg K- |
| Porphyromonas gingivalis K1 HG 86/W83* | Pg K1 |
| Porphyromonas gingivalis K6 HG 1691* | Pg K6 |
| Prevotella intermedia HG 110* | Pi |
| Prevotella nigrescens HG 70* | Pn |
| Staphylococcus aureus ATCC 2592 | Sa |
| Streptococcus mutans HG 708* | Sm |
| Streptococcus sanguinis HG 1471* | Ss |
| Tannnerella forsythia ATCC 43037 | Tf |
| Veillonella parvula HG 318* | Vp |

*Clinical isolates.
incubated for 7 days at 37°C under anaerobic conditions (10% CO₂, 10% H₂, and 80% N₂). The concentration at which growth was visibly inhibited was defined as the MBC.

**Pilot clinical study**
The study protocol was approved by the Medical Ethics Committee of the Academic Medical Center (AMC) of Amsterdam (NL37567.018.11) and registered at the Dutch trial register under the number NTR3145. The study followed the instructions based on the declaration of Helsinki. That statement acts as a starting point in subject recruitment.

**Study population**
Participation in this study was voluntary. Before enrollment all participants were given oral and written information about the products and the reason, aim, duration, demands of benefits and possible harm. After signing a declaration of informed consent, 26 systemically healthy participants meeting the inclusion criteria agreed to participate in the study.

All participants (non-dental students, ≥ 18 years) had to be dentate with at least 5 evaluable teeth per quadrant excluding prosthetic crowns. To include a population with high plaque scores at the start of the experimental period, participants were selected that had an overnight plaque score of 2 or higher as assessed according to Modified Quigley & Hein Plaque index (Paraskevas et al., 2007). Exclusion criteria were: oral mucosal lesions, orthodontic appliances, removable (partial) dentures, and overhanging margins of dental restorations (clinically assessed with a periodontal probe), the use of antibiotics during the last 6 months, Dutch Periodontal Screening Index (Mantilla Gomez et al., 2001) (DPSI) ≥ 3+ (periodontal pockets > 5 mm with bleeding on probing and gingival recession), the use of medication possibly influencing normal gingival health, pregnancy and smoking.

**Test compound**
According to the manufacturer, the hydro-carbon-oxo-borate compound AX had the following ingredients: aqua, sodium lauryl sulfate, PEG-40 hydrogenated castor oil, sodium gluconate, cellulose gum, aroma, sodium citrate, magnesium sulfate, sodium perborate, sodium methylparaben, citric acid, sodium chloride, sodium fluoride, sodium saccharin (NGen Oral Pharma, www.ngenpharma.com¹; van den Bosch, 2000, US patent number 6,017,515).

**Study design**
The study started with a pre-experimental appointment (1 month prior to baseline) during which dental plaque was scored and sampled with the intention to assess the consistency of collected plaque scores and microbiological data relative to the baseline. At baseline, dental plaque was again scored and sampled. In addition, the level of bleeding on marginal probing was assessed as a descriptive of the oral health status of the included subjects. After the baseline measurements, a professional prophylaxis was performed by a dental hygienist as described in detail by Slot et al. (2010) in order to start the experiment with equally clean teeth. Following the prophylaxis, a one-week non-brushing experimental period of undisturbed plaque accumulation was started. With respect to oral hygiene the participants were only allowed rinsing with the distributed mouthwash (AX). Each subject received an instruction form on how to use the intervention product and the first rinse was performed under supervision. Participants were instructed to rinse twice daily (morning and evening) for 1 min and not to rinse, drink or eat for at least 30 min thereafter. No other form of oral hygiene during the subsequent week was allowed, including chewing gum (Keukenmeester et al., 2014) or any xylitol containing sweets or gum (Soderling, 2009).

**Clinical assessments**
In the study a partial-mouth model (Bentley and Disney, 1995) was used. Two contra-lateral randomly chosen quadrants (www.random.org) served for the collection of dental plaque biofilm that was not disturbed by scoring or the disclosing solution (one in the upper and one in the lower jaw; Heijnsbroek et al., 2006; Van Leeuwen et al., in press).

The two opposing contra-lateral quadrants were used for the clinical plaque assessments. All teeth in each of the two quadrants were examined except third molars. Scoring was performed by two experienced examiners each responsible for scoring one clinical parameter (plaque or bleeding) separately. For plaque scores teeth were disclosed with a 1% erythrosine solution. Plaque was assessed at six sites per tooth on a six-point scale using the Quigley & Hein’s plaque index (Quigley and Hein, 1962) as modified by Turesky et al. (1970) and further modified by Lobene et al. (1982), in which the absence or presence of plaque was recorded on a 0–5 scale (0 = no plaque, 5 = plaque covering more than two-thirds of the tooth surface) and described in detail by Paraskevas et al. (2007). At the baseline appointment the level of oral health was assessed in the two contra-lateral quadrants that had previously been sampled for supragingival plaque using the Bleeding on Marginal Probing (BOMP) score (van der Weijden et al., 1994a,b; Lie et al., 1998). Bleeding was elicited with a WHO-approved ball-ended probe (Ash Probe EN15, Dentsply International, York, PA, USA). The absence or presence of bleeding was scored within 30 s of probing on a scale of 0–2 (0 = non-bleeding, 1 = pinprick bleeding, 2 = excess bleeding).

**Sampling procedure**
Since it is imperative to characterize differences in microbial composition among specific oral locations, supragingival dental plaque was collected from the buccal sites of four pre-selected teeth being the same at all three assessments (first molar and canine, upper and lower jaw). Dental plaque was carefully collected by an experienced examiner with a sterile microbrush (Microbrush International, Grafton, USA) per tooth moving over the enamel surface from the mesial to distal curvature of the tooth crown along the gingival margin and tooth-surface border. The tip of each of the four microbrushes was clipped off and placed in a single vial containing RNAProtect Bacteria reagent (Qiagen, Hilden, Germany). Samples were coded, kept on ice until transfer within 2 h to the laboratory.

**DNA extraction, amplicon preparation, and pyrosequencing**
Of the 72 clinical samples belonging to 25 subjects, 6 samples were lost due to technical reasons. DNA was extracted
with the AGOWA mag Mini DNA Isolation Kit (AGOWA, Berlin, Germany) as described previously (Crielaaerd et al., 2011). Barcoded amplicon libraries of the small subunit ribosomal RNA gene hypervariable region V5–V7 were generated for each of the individual sample as described previously (Kranefold et al., 2012), pooled and sequenced by means of the Genome Sequencer FLX Titanium system (Roche Molecular Diagnostics). The sequencing data was processed using Quantitative Insights Into Microbial Ecology (QIIME) (Caporaso et al., 2010) version 1.5.0. The reads were denoized using Denoiser version 1.3.0 (Reeder and Knight, 2010) and checked for chimeric sequences using UCHIME version 4.2.40 (Edgar et al., 2011). The results of the de novo and the reference-based approach were combined and reads marked as chimeric were removed. Sequences were clustered in operational taxonomic units (OTUs) at 97% similarity.

Statistical analyses
The statistical package SPSS software version 19.0 was used to perform statistical analyses. The effect of AX on bacterial strains in the agar diffusion assay was analyzed for each AX concentration relative to the effect of 0.2% CHX for each bacterial strain (Mann–Whitney test). Differences among strains per-compound were calculated using One-Way ANOVA and Tukey B post-hoc test.

For the clinical study, the mean plaque score and gingival bleeding score were calculated first per participant. Additionally the mean bleeding score at baseline for the sampled teeth was calculated. Plaque scores were tested for normality using the Shapiro–Wilk test. Non-parametric Wilcoxon Signed Rank test was performed to test for differences in plaque scores between the three visits: pre-experimental, baseline and post-experimental.

To normalize the microbial data for comparisons among different samples and to avoid the effect of variable sample size on the diversity analyses, a randomly subsampled data set of 850 reads per sample was created. This resulted in exclusion of additional five samples with less than 850 reads/sample. PAST software (Hammer et al., 2001) was used to calculate Shannon diversity index, which takes into account the abundance of each OTU, as well as the number of OTUs. The normality of the diversity index data was assessed using Shapiro–Wilk test. Paired samples T-test was used to compare the diversity indices between the three time points. OTU-significance paired samples T-test implemented in QIIME 1.5.0 was used to compare the abundances of OTUs at baseline and post-experimental samples. Only those OTUs that were present in at least 10 samples were included in the analyses, resulting in 75 comparisons. The p-values were corrected for these multiple comparisons using Bonferroni correction. P-values below 0.05 were considered statistically significant.

To visualize microbial profile data, principal component analysis (PCA) was used in PAST. The OTU abundances were log2 transformed to normalize the data distribution.

RESULTS
IN VITRO STUDY
Based on the size of the inhibition zone (mm), the efficacy of CHX was greater than that of AX at all concentrations tested and for all bacterial strains (p < 0.05). AX showed high variation in inhibition (Figure 1), which was statistically significant among various strains (Table 2). Streptococcus mutans, Lactobacillus acidophilus and Streptococcus sanguinis were the least affected (inhibition zone 0–0.3 mm), while Prevotella nigrescens (9 mm) and Prevotella intermedia (9 mm)—the most p < 0.05 (Table 2).

All tested strains were inhibited by CHX and the differences in inhibitory activity among strains were less pronounced than for AX (Table 2). Porphyromonas gingivalis K- was the most affected (14 mm) and Staphylococcus aureus—the least (6 mm). None of the strains were inhibited by the AX blank (0 mm).

For most strains the MICs and MBCs for AX were ≤638 mg/l SP. Except for L. acidophilus—2550 mg/l SP, S. aureus and S. sanguinis—1275 mg/lSP (Table 3). The MBCs and MICs for AX were nearly the same (Table 3).

PILOT CLINICAL STUDY
Of 26 participants initially enrolled in the study, one participant dropped out for a reason unrelated to the study (Table 4, Figure 2). The duration of overnight plaque accumulation assessed at the pre-experimental and the baseline visits ranged from 10 to 16 h with an average of 13 h (SD 2.9). At the baseline appointment, the mean level of gingival health of the participants, as assessed by Bleeding on Marginal Probing BOMP in two contra-lateral quadrants, was 1.15 (SD 0.33) (Table 4). The mean bleeding scores at the sampled teeth (total of 12 bacular sites from four pre-selected teeth) was 0.98 (SD 0.43), which corresponds to 51% bleeding (SD 23).

Plaque scores did not differ significantly between the pre-experimental visit and baseline (p = 0.193), while plaque scores increased significantly (p = 0.014) during a week without any additional oral hygiene measures but with twice-daily use of AX mouthwash (Table 5).

Compliance to the rinsing protocol was assessed by weighing the bottles at the baseline and 7 days later at the post-experimental visit. The difference was on average 140 g (±14 g), which implied on average 14 servings of 10 ml complying with the individual instructions for use given.

In total 19 participants provided evaluable microbiological data. The data of three participants were excluded due to the technical reasons in sample processing, and another three—due to low reads (<850) per sample in one of the samples after the filtering steps of the sequencing data. The remaining 54 samples had on average 3135 reads/samples (SD 1047). The total of 169,309 reads were classified into 15 phyla, with Actinobacteria (39% of the reads) and Firmicutes (31%) dominating the data, followed by Proteobacteria (19%), Bacteroidetes (7.5%), Fusobacteria (3.1%) and Candidate division TM7 (0.3%).

After subsampling at 850 reads/sample, the diversity and taxonomic comparisons among the three visits (pre-experimental, baseline and post-experimental) were performed. Shannon diversity index, taking into account the abundance of each OTU as well as the number of OTUs, significantly increased from pre-experimental to baseline visit from 2.67 (SD 0.29) to 2.79 (SD 0.29) (p = 0.02) and significantly decreased at post-experimental visit to 2.09 (SD 0.39) (p < 0.001).

Genera Corynebacterium (21% of reads) and Streptococcus (16–20%) dominated the pre-experimental and baseline samples. Both of these genera were significantly affected by the treatment.
FIGURE 1 | Effects of Ardox-X®-technology (AX), Blank AX and Chlorhexidine (CHX) on inhibition of oral bacterial strains in agar diffusion assay. Inhibition zone size is expressed in mm (mean of triplicate experiment, except duplicate for Aa and Fn). The strains (Table 1) used were: Pm, Parvimonas micra; Porphyromonas gingivalis (Pg K1), (Pg K-6), (Pg K6); An, Actinomyces naeslundii; Fn, Fusobacterium nucleatum; Cr, Campylobacter rectus; Sa, Staphylococcus aureus; Aa, Aggregatibacter actinomycetemcomitans; La, Lactobacillus acidophilus; Vp, Veillonella parvula; Ss, Streptococcus sanguinis; Sm, Streptococcus mutans; Pi, Prevotella intermedia; Pn, Prevotella nigrescens; Tf, Tannerella forsythia.

Table 2 | Results of the Agar Diffusion assay, performed in triplicate.

| Strain | 0.2% CHX | 0.12% CHX | 5 SE | 7 SE | 10 SE | 15 SE | 20 SE |
|--------|----------|-----------|------|------|-------|-------|-------|
| Mean (SD) | Diff. | Mean (SD) | Diff. | Mean (SD) | Diff. | Mean (SD) | Diff. | Mean (SD) | Diff. | Mean (SD) | Diff. | Mean (SD) | Diff. |
| An | 11 (0) | cd | 9 (1) | ab | 0 NA | b | 0 NA | cd | 1 (1) | b | 0 NA | d | 1 (1) | cde |
| Cr | 10 (1) | cde | 9 (1) | cd | 1 (1) | ba | 1 (1) | d | 2 (1) | b | 0 NA | e | 0 NA | fg |
| La | 10 (2) | def | 8 (1) | fgh | 1 (2) | ba | 1 (1) | bcd | 1 (1) | cd | 2 (1) | bcde | 2 (1) | def |
| Pm | 9 (1) | def | 8 (1) | ab | 1 (1) | ba | 2 (1) | abc | 2 (1) | abc | 3 (1) | abcde | 4 (1) | cd |
| Pg K- | 14 (1) | a | 13 (1) | ba | 1 (1) | b | 2 (1) | abc | 1 (1) | abc | 2 (1) | abcde | 2.7 (0.6) | de |
| Pg K1 | 14 (1) | a | 12 (1) | ab | 0.7 (0.6) | ba | 1 (1) | cd | 2 (0) | bd | 2 (1) | bcde | 2 (1) | de |
| Pg K6 | 13 (1) | abc | 12 (0) | abc | 1 (1) | ba | 2 (1) | abc | 2 (1) | abc | 3 (1) | abcde | 4 (1) | cd |
| Pi | 11 (1) | bcd | 10 (2) | bcd | 2.7 (0.6) | a | 4 (1) | abc | 5 (1) | a | 7 (1) | a | 9 (1) | a |
| Pn | 13 (1) | bac | 11 (1) | abcd | 3 (1) | a | 2.7 (0.6) | abc | 6 (1) | a | 7 (2) | a | 9 (2) | a |
| Sa | 6 (1) | f | 6 (0) | f | 0 NA | b | 0 NA | b | 0 NA | d | 0 NA | 0.3 (0.6) | de | 1 (1) | efg |
| Str | 9 (1) | cdef | 9 (1) | efg | 0 NA | b | 0 NA | da | 0 NA | d | 0 NA | 0 NA | e | 0 NA | g |
| Sa | 7 (1) | ef | 6 (1) | gh | 0 NA | b | 0 NA | da | 0 NA | d | 0 NA | 0 NA | e | 0 NA | fg |
| Tf | 13 (1) | ab | 12 (0) | abc | 1 (1) | ba | 1 (1) | abc | 2 (1) | bc | 3 (1) | abc | 4 (1) | cd |
| Vp | 9 (1) | def | 8 (2) | fgh | 0 NA | b | 1 (1) | d | 2 (1) | bc | 2 (0) | bcde | 3 (0) | de |
| Aa** | 10 (1) | cd | 8 (1) | cd | 0 NA | d | 1 (1) | cd | 1 (1) | b | 1 (1) | cd | 2 (1) | cd |
| Fn** | 12 (1) | cde | 11 (1) | cd | 1 (1) | cde | 2.5 (0.6) | cd | 3.5 (0.7) | cde | 5 (1) | cde |

Mean size of the inhibition zones (mm) and standard deviation. Diff., Different letters indicate statistically significant difference among the different bacterial strains per-compound (within each column) (p < 0.05; ANOVA, Tukey B-test). *n = 6; **Excluded from analysis (n = 2); NA, not applicable; SE, standard equivalent units.

period: Corynebacterium was reduced to 2% and Streptococcus—increased to 32% (Figure 3). Additionally, genus Veillonella showed significant increase from 2–3 to 12% after the treatment, while genus Derxia showed significant decrease from 3 to 0.7%, respectively (Figure 3). Genus Leptotrichia was nearly absent after the experimental period, while it constituted approximately 2% of the reads at the pre-experimental and baseline visits. Genus Prevotella was present at a very low proportion—between 1 and
Next, the microbiome profile data were ordinated by applying principal component analysis (PCA) (Figure 4). The first principal component (PC1) explained 27% of the overall variance among the samples and showed a clear separation of the pre-experimental (black dots, Figure 4) and baseline samples (blue dots, Figure 4) from the post-experimental samples (red dots in Figure 4). The second component explained 11% of the total variance and separated the samples belonging to subjects Nr 1 and Nr 31 from the rest (Figure 4).

**DISCUSSION**

The *in vitro* experiments of this study indicated that oxygen-releasing compound Ardox-X® technology (AX) selectively inhibits oral bacteria, with anaerobe Gram-negative species being the most sensitive. These promising findings were further tested *in vivo*, during a pilot clinical study with experimental period without any oral hygiene measures but twice-daily rinse with mouthwash containing AX. After a week of non-brushing, the plaque scores increased, while the microbial composition showed a shift toward compositionally less diverse plaque, dominated by primary colonizing genera *Streptococcus* and *Veillonella* compared to the *Corynebacterium* dominated plaque at the baseline.

It has been proposed that in order to study the effects of a mouthwash, a population with a high amount of plaque should be studied (Wennstrom, 1988). The study population therefore included individuals that proved to be good plaque formers at the screening visit. Moreover, it is known that the periodontal condition affects the rate of supragingival plaque forming (Hillam and Hull, 1977; Rowshani et al., 2004). Participants showed to have moderate gingivitis at baseline whereby 51% of the sampled sites were bleeding on marginal probing. The one-month interval between the pre-experiment assessment and baseline did not result in significant changes in plaque scores or in plaque composition of the study population. This is in line with previous studies, which have demonstrated the stability of the oral microbiome (Zhou et al., 2013). Microbial composition of the supragingival plaque in this gingivitis population 1 month before the experiment and at the baseline resembled mature plaque (Haffajee et al., 2009) and plaque associated with gingivitis (Huang et al., 2011). The major taxon in these samples was identified as *Corynebacterium*, a Gram-positive, facultatively anaerobic bacterium that resembles Gram-negatives with respect to the lipid layer in the cell membrane (John, 1984). *Corynebacterium* is associated with mature plaque and is found in dental calculus (Moorer et al., 1993).

The participants of the classical experimental gingivitis model (Loe et al., 1965; Theilade et al., 1966) received a prophylaxis and subsequently refrained from oral hygiene for 21 days inducing an acute stage of inflammation in otherwise healthy subjects. For the present study a seven-day model was chosen since the purpose was not to change the level of gingival health but to assess the effects on the microbial composition of undisturbed plaque. In the absence of oral hygiene, bacterial re-colonization increases after professional oral hygiene reaming or exceeding pre-prophylaxis levels at 2 days (Uzel et al., 2011) and *de novo* plaque formation reaches a stable microbial community between 4 and 7 days (Uzel et al., 2011). Higher diversity of mature...
supragingival plaque compared to younger plaque has been found in a recent experimental gingivitis study (Kistler et al., 2013). In the present study after the baseline assessment, the participants received a thorough professional oral hygiene and were not allowed to brush their teeth for 1 week. Instead, they were asked to perform a twice daily rinsing with AX-containing mouthwash. As expected, the plaque amount increased during the experimental period. The composition of the sampled plaque also changed impressively, whereby microbial diversity had decreased significantly, when compared to the pre-experimental and baseline visits. Genus Corynebacterium was considerably reduced, while streptococci, Veillonella and Haemophilus—all health-associated primary colonizers (Colombo et al., 2009; Simon-Soro et al., 2013)—dominated the post-experimental plaque.

In vitro diffusion and susceptibility tests showed that AX is highly selective in inhibiting oral bacteria. The Gram-negative anaerobes such as prevotellas, but also Veillonella, Tannarella, Campylobacter, Fusobacterium, and Porphyromonas were highly sensitive, while streptococci and lactobacilli, facultative anaerobe
Gram-positive bacteria, were not inhibited even by the highest dose of AX tested in the diffusion test. In the clinical samples genus Prevotella were found at very low levels throughout the study and no effect of AX was discernible. However, other Gram-negative taxa such as genera Derxia and Leptotrichia, as well as OTUs classified as Cardiobacterium (OTU#245) and Capnocytophaga (OTU#251) were significantly reduced during the experimental period. Unfortunately, in vitro tests did not include any genus Corynebacterium species which allows only for speculation whether this Gram-positive bacterium with the characteristics of Gram-negatives (John, 1984) was also highly susceptible to exposure to AX. Alternatively its nearly complete elimination from the post-experimental plaque samples could have other reasons for instance its growth could have
been inhibited due to ecological shifts in the entire community (Bradshaw et al., 1989). Another intriguing bacteria was Veillonella—anaerobe Gram-negative bacteria, associated with early supragingival plaque (Li et al., 2004; Haffajee et al., 2009). Although Veillonella was found to be susceptible to AX in in vitro testing, this genus showed a significant increase after the experimental period with twice-daily exposure to the AX mouthwash. This could be attributed to the “pioneering” function of this bacteria; it is found in healthy individuals, in young supragingival plaque, in similar proportions with streptococci (Keijser et al., 2008; Haffajee et al., 2009). Veillonellae are secondary fermenters—they consume lactic acid produced during glucose fermentation by streptococci (Keller and Surette, 2006; Periasamy and Kolenbrander, 2010) and produce other, weaker acids such as acetic and propionic acid. By doing so, the environmental conditions are created that promote growth of both of these genera (Bradshaw et al., 1989). The most likely explanation of the increase of genus Veillonella during the experimental period, although sensitive to direct exposure to AX in vitro, could be related to this ecologically beneficial relationship with streptococci.

The selective inhibition of oral bacteria by AX is of interest with respect to gingival and periodontal diseases, since infections associated with Gram-negatives would be selectively suppressed whereas the microorganisms regarded as more beneficial for periodontal health such as streptococci and lactobacilli would not. Several in vitro studies (Teughels et al., 2007; van Essche et al., 2012) and recent clinical studies (Iniesta et al., 2012; Teughels et al., 2013; Yanine et al., 2013) have suggested that these allegedly beneficial bacteria can cause antagonism toward Gram-negative bacteria.

In the agar diffusion assay, AX had significantly lower inhibitory effect than CHX. The activity of AX could have been limited to a short period right after its administration until the active component is broken down and oxygen is released. CHX is known to retain its activity for a longer time period after a single application in vitro (Carrilho et al., 2010). The only other study that has assessed the antimicrobial effect of AX, showed that the AX containing product had higher antimicrobial capacity than chlorhexidine toward monospecies bacterial biofilm and microcosm obtained from pooled saliva (Ntrouka et al., 2011).

So far, chlorhexidine (CHX) has proven to be the most effective antimicrobial agent in clinical dentistry and is considered as the “gold standard” disinfectant in dental research (Jones, 1997; Arweiler et al., 2001). Although it is widely used in periodontics and is among the most effective compounds preventing plaque formation (Addy, 1986), it has several side effects (Keijser et al., 2003; Gurgan et al., 2006) and therefore may result in poor rinsing compliance by patients (Addy and Moran, 1985; Cortellini et al., 2008; Van Strydonck et al., 2012). Optimizing anti-plaque agents, reducing their side effects while at the same time taking care that the oral microbiota are kept in balance with oral health has initiated interest in the development of other chemotherapeutical agents. Interestingly, AX showed selective inhibition of oral bacteria that may contribute to this demanding balance and deserves further investigation.

The lack of controls is a major limitation of this study that could have potential bias on the interpretation of this study outcomes. This pilot however indicates a potential rationale for more elaborate studies with a randomized clinical trial protocol that would include both a positive control such as CHX, and a negative control without any antimicrobial effects. The potential effect of AX on reductions in both the clinical manifestations of gingivitis and the inhibition of or reduction of plaque or plaque pathogenicity still needs to be demonstrated. For that purpose a 21 days experimental gingivitis model could be used or alternatively a 4-week trial among gingivitis subject as proposed by the American Dental Association in their Acceptance Guidelines of Chemotherapeutic Products for Control of Gingivitis (ADA, Acceptance Guidelines, 2008).

In conclusion, a mouthwash containing the oxygenating agent Ardox-X® technology showed potential for selective inhibition of oral bacteria. Twice-daily exposure for 1 week to this mouthwash resulted in a shift in the microbial composition toward a less diverse and less mature plaque. The clinical consequences of this shift in the oral microbiota need to be established.

FUNDING
ACTA Research BV received financial support from NGen Oral Pharma N. V., Curacao, for the role of the Departments of Periodontology and Preventive Dentistry of ACTA in this project. NGen Oral Pharma N. V., Curacao, provided study products. The authors report that this company had no influence on the design, content, results and publication of this study.

ACKNOWLEDGMENTS
We thank Nienke Hennequin—Hoenderdos and Dagmar Else Slot for coordinating the clinical study and Eveline van der Sluijs for her support during the process for the Medical Ethical Committee approval and the following persons for their contribution to the clinical study: Esther Martin and Guylaine van Anraat (Department of Periodontology Research group Prevention and Therapy of ACTA) and Wendy de Wit (Department of Preventive Dentistry at ACTA).

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: http://www.frontiersin.org/journal/10.3389/fcimb.2014.00095/abstract
(1) seqs_rct_rep_set.fasta with the representative sequences of each OTU;
(2) otu_table_rct_not_subsampled.txt file with the OTU-table containing the list of OTUs and their respective taxonomical assignment and read abundances per each sample.

REFERENCES
Addy, M. (1986). Chlorhexidine compared with other locally delivered antimicrobials. A short review. J. Clin. Periodontol. 13, 957–964. doi: 10.1111/j.1600-051X.1986.tb01434.x
Addy, M., and Moran, J. (1985). Extrinsic tooth discolouration by metals and chlorhexidine. II. Clinical staining produced by chlorhexidine, iron and tea. Br. Dent. J. 159, 331–334. doi: 10.1038/sj.bdj.4805722
Arweiler, N. B., Netuschil, L., and Reich, E. (2001). Alcohol-free mouthrinse solutions to reduce supragingival plaque regrowth and vitality. A controlled
